A first-in-human proof-of-concept study with NVDX3, an osteogenic implant of human allogenic origin, in the treatment of distal radius fractures in adults.

2023-508321-27-00 Phase I and Phase II (Integrated) - First administration to humans Ended

Start 8 Aug 2023 · End 19 Dec 2024 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ended
Participants planned 10
Countries 1
Sites 1

Distal radius fractures

Key facts

Sponsor
Novadip Biosciences
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
8 Aug 2023 → 19 Dec 2024
Decision date (initial)
2024-01-18
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-508321-27-00
EudraCT number
2022-002304-21
ClinicalTrials.gov
NCT05987033

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Distal radius fractures

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novadip Biosciences

Sponsor organisation
Novadip Biosciences
Address
Rue Granbonpre 11
City
Mont-Saint-Guibert
Postcode
1435
Country
Belgium

Scientific contact point

Organisation
Novadip Biosciences
Contact name
Denis Dufrane

Public contact point

Organisation
Novadip Biosciences
Contact name
Denis Dufrane

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Luxembourg Ended 10 1
Rest of world 0

Investigational sites

Luxembourg

1 site · Ended
Centre Hospitalier de Luxembourg
Orthopedics and traumatology, rue Ernest Barblé 4, L-1210, Luxembourg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Luxembourg 2023-08-08 2024-12-19 2023-08-08 2023-12-20

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-21 Luxembourg Acceptable
2024-01-17
2024-01-18
2 SUBSTANTIAL MODIFICATION SM-2 2024-12-10 Luxembourg Acceptable
2025-02-10
2025-02-11